Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) announced that its partner STADA Arzneimittel AG's subsidiary, Spirig HealthCare AG, has received approval from the Swiss Medicines Agency for the marketing authorization of tofacitinib citrate tablets, marking a significant milestone in the treatment of autoimmune diseases [1] Group 1 - Tofacitinib citrate tablets are the world's first approved oral Janus kinase (JAK) inhibitor, classified as a targeted synthetic disease-modifying antirheumatic drug (DMARD) [1] - The drug works by inhibiting the intracellular JAK signaling pathway, thereby modulating immune responses [1] - It is primarily used for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, which are all autoimmune diseases [1]